Media Update: Sanofi completes closing for potential first-in-class vaccine against extraintestinal pathogenic E.coli (ExPEC)

PUBLISHED NOV 9, 2023
BY SANOFI

Sanofi completes closing for potential first-in-class vaccine against extraintestinal pathogenic E. coli (ExPEC)

Paris, November 9, 2023. Sanofi announces today completion of closing for its collaborative agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company to develop and commercialize the vaccine candidate for extraintestinal pathogenic E. coli (9-valent) (ExPEC9V).

Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis, causing approximately 10 million cases of invasive ExPEC disease annually, worldwide.1,2 It is associated with increased hospitalizations, mortality and antimicrobial resistance resulting in significant healthcare and societal costs.3,4

Executive Vice President, Vaccines, Sanofi

> At Sanofi, we believe in the power of partnership to deliver true innovation. In this case, we're bringing together Janssen's robust science and Sanofi's worldwide manufacturing footprint and expertise in launching innovative vaccines. We look forward to delivering this potential first-in-class vaccine designed to help older adults around the world live longer, healthier lives.

ExPEC9V is currently being assessed via the Phase 3 E.mbrace trial which continues to enroll patients. Learn more about the trial here: https://classic.clinicaltrials.gov/ct2/show/NCT04899336

1 Russo TA and Johnson JR. Medical and economic impact of extraintestinal infections due to Escherichia coli: focus on an increasingly important endemic problem. Microbes Infect. 2003;5:449–456.

2 Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395(10219):200-211. doi:10.1016/S0140-6736(19)32989-7

3 O'Neill J. Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations. Review on Antimicrobial Resistance. Available at: https://amr-review.org/sites/default/files/AMR%20Review%20Pa per%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf. Last accessed: October 2022.

4 Hernandez-Pastor L, Geurtsen J, Baugh B, et al. Economic burden of invasive Escherichia coli disease among older adult patients treated in hospitals in the United States. J Manag Care Spec Pharm. 2023;29(8):873-883. doi:10.18553/jmcp.2023.29.8.873

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Sandrine Guendoul | + 33 6 25 09 14 25 |sandrine.guendoul@sanofi.com

Sally Bain | + 1 617 834 6026 |sally.bain@sanofi.com

Eva Schaefer-Jansen | + 33 7 86 80 56 39 |eva.schaefer-jansen@sanofi.com

Arnaud Delépine | + 33 6 73 69 36 93 |arnaud.delepine@sanofi.com

Corentine Driancourt | + 33 6 40 56 92 21 |corentine.driancourt@sanofi.com

Felix Lauscher | + 1 908 612 7239 |felix.lauscher@sanofi.com

Tarik Elgoutni| + 1 617 710 3587 |tarik.elgoutni@sanofi.com

Nathalie Pham | + 33 7 85 93 30 17 |nathalie.pham@sanofi.com

Sanofi Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and

Cautionary Statement Regarding Forward-Looking Statements

in Sanofi’s annual report on Form 20-F for the year ended December 31, 2022. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Press release distributed by Wire Association on behalf of Sanofi, on Nov 9, 2023. For more information subscribe and follow us.

Media Assets

Embedded Media

Visit the online press release to interact with the embedded media.

https://wireassociation.eu/newsroom/sanofi/releases/en/media-update-sanofi-completes-closing-for-potential-first-in-class-vaccine-against-extraintestinal-pathogenic-ecoli-expec-1518

Sanofi

Newsroom: https://wireassociation.eu/newsroom/sanofi
Website: https://www.sanofi.com/
Primary Email: uk-mr@sanofi.com

Social Media

Twitter - https://twitter.com/sanofi
Youtube - https://www.youtube.com/user/sanofiaventisTVen
Linkedin - https://www.linkedin.com/company/sanofi
Instagram - https://www.instagram.com/sanofi/
